{"id":"folfox-plus-bevacizumab-and-reolysin","safety":{"commonSideEffects":[{"rate":"30-50%","effect":"Fatigue"},{"rate":"20-40%","effect":"Nausea and vomiting"},{"rate":"10-30%","effect":"Diarrhea"},{"rate":"10-20%","effect":"Neutropenia"},{"rate":"5-15%","effect":"Anemia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Folfox is a combination of fluorouracil, leucovorin, and oxaliplatin, which work together to inhibit thymidylate synthase and DNA repair, ultimately leading to cell death. Bevacizumab is a monoclonal antibody that targets vascular endothelial growth factor (VEGF), preventing angiogenesis and tumor growth. Reolysin is a reovirus that selectively infects and kills cancer cells by inducing apoptosis.","oneSentence":"Folfox plus Bevacizumab and reolysin is a combination chemotherapy regimen that targets rapidly dividing cancer cells and inhibits angiogenesis.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:32:33.637Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic colorectal cancer"}]},"trialDetails":[{"nctId":"NCT01622543","phase":"PHASE2","title":"Reolysin in Combination With FOLFOX6 and Bevacizumab or FOLFOX6 and Bevacizumab Alone in Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"Canadian Cancer Trials Group","startDate":"2012-10-26","conditions":"Colorectal Cancer","enrollment":109}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"Folfox plus Bevacizumab and reolysin","genericName":"Folfox plus Bevacizumab and reolysin","companyName":"Canadian Cancer Trials Group","companyId":"canadian-cancer-trials-group","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Folfox plus Bevacizumab and reolysin is a combination chemotherapy regimen that targets rapidly dividing cancer cells and inhibits angiogenesis. Used for Metastatic colorectal cancer.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}